ReviewOncology reviews2026
Cardio-oncology in multidisciplinary synergy: addressing the rising burden of cancer therapy-related cardiovascular toxicity (CTR-CVT) in advancing oncology practices.
Review in Oncology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Improvements in cancer detection and the development of modern anticancer therapies have markedly increased survival rates among patients with malignancies, resulting in a rapidly expanding survivor population. Alongside these advances, cardiovascular complications related to cancer treatment have emerged as a major clinical concern, significantly affecting long-term morbidity and mortality. The growing intersection between oncology and cardiovascular medicine has led to the development of cardio-oncology, a multidisciplinary field focused on balancing effective cancer treatment with cardiovascular safety. This review discusses current perspectives on the mechanisms, risk assessment, prevention, surveillance, and management of cancer therapy-related cardiovascular toxicity (CTR-CVT) in contemporary oncology practice. Methods: A narrative literature review was conducted using electronic databases including PubMed, Scopus, and ScienceDirect. Relevant studies published between 2015 and 2025 were identified using predefined keywords related to cardio-oncology and cardiovascular toxicity. Eligible articles included clinical trials, observational studies, guidelines, and systematic reviews focusing on CTR-CVT. Studies were screened based on relevance, and key findings were synthesized narratively. Key-content and findings: CTR-CVT comprises diverse cardiovascular complications associated with both conventional and emerging anticancer therapies. Risk stratification tools such as HFA-ICOS facilitate early identification of high-risk patients and guide surveillance strategies. Early multidisciplinary management, particularly for severe toxicities such as immune checkpoint inhibitor-associated myocarditis, is essential to optimize both cardiovascular and oncologic outcomes. Conclusion: CTR-CVT represents a major challenge in contemporary oncology care. A multidisciplinary cardio-oncology approach integrating early risk assessment, preventive strategies, and structured monitoring is essential to balance oncologic efficacy with cardiovascular safety. Future research should focus on personalized risk prediction and targeted cardioprotection strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.